Moraga, Calif. January 6, 2016—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that the company will present at the Biotech Showcase 2016 Conference, which will be held in San Francisco, CA next week. The presentation will be made by Charles Yeomans, president and chief executive officer of Trigemina, and Shashidar Kori, MD, chief medical officer, and will occur at 11:45 a.m. PST on Tuesday, January 12, 2016.
Trigemina is developing easy-to-use, highly-targeted, nose-to-brain therapies for patients with debilitating CNS disorders. Our platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders with high unmet medical need. Our lead product, a site-specific blocker of CGRP release in the CNS, is in late-stage development for the prevention of high frequency episodic and chronic migraine in both adults and adolescents.
President and CEO, Trigemina
Cook Williams Communications, Inc.